AI-based Biotechnology company RevolKa and pharmaceutical company Daiichi Sankyo and have entered a drug development partnership. Details of this agreement and financial terms were undisclosed.
According to the partnership, RevolKa will be committed to creating and delivering highly functional proteins, leveraging Daiichi Sankyo’s proprietary protein engineering platform technology, called "aiProtein," an AI-integrated protein engineering technology.
Tokyo-based RevolKa is a biotechnology company specializing in the development of highly functional proteins using AI. The company leverages its proprietary aiProtein technology to accelerate the creation of engineered proteins. RevolKa’s pipeline includes several programs spanning therapeutic areas of immuno-oncotherapy, rare diseases, oncology, and infectious diseases.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.